Li-Fraumeni syndrome in adult patients with acute lymphoblastic leukemia

被引:0
作者
Zarubina, Kseniia, I [1 ]
Parovichnikova, Elena N. [1 ]
Surin, Vadim L. [1 ]
Pshenichnikova, Olesia S. [1 ]
Gavrilina, Olga A. [1 ]
Isinova, Galina A. [1 ]
Troitskaya, Vera V. [1 ]
Sokolov, Andrei N. [1 ]
Galtseva, Irina, V [1 ]
Kapranov, Nikolai M. [1 ]
Davydova, Juliia O. [1 ]
Obukhova, Tatiana N. [1 ]
Nikulina, Elena E. [1 ]
Sudarikov, Andrei B. [1 ]
Savchenko, Valerii G. [1 ]
机构
[1] Natl Res Ctr Hematol, Moscow, Russia
关键词
acute lymphoblastic leukemia; hereditary predisposition; Li-Fraumeni syndrome; TP53; mutations; CANCER-RISK; HEMATOLOGIC MALIGNANCIES; BREAST-CANCER; MUTATIONS; PREDISPOSITION; CHILDREN; MOTHERS;
D O I
10.26442/00403660.2021.07.200913
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Li-Fraumeni syndrome (LFS) is a rare, autosomal dominant, hereditary disorder that is characterized by an increased risk for certain types of cancer, acute lymphoblastic leukemia (ALL), particularly. Germline TP53 mutations are associated with LFS. Genetic counseling and follow-up is essential for patients with LFS and their relatives. Special therapeutic approaches are needed for treatment of oncological disease in these patients. The article presents a series of clinical cases of patients with ALL and SLF, considers general issues of diagnosis and treatment of adult patients with this hereditary genetic syndrome. Aim. Describe clinical observations of patients with acute lymphoblastic leukemia (ALL) and LFS and consider general issues of diagnosis and treatment of adult patients with LFS and ALL. Materials and methods. TP53 gene mutations were screened using Sanger sequencing in 180 de novo patients with Ph-negative (B- and T-cell) and Ph-positive ALL treated by Russian multicenter protocols (ALL-2009, ALL-2012, ALL-2016) at the National Research Center for Hematology, Moscow, Russia, and at the hematology departments of regional clinics of Russia (multicenter study participants). Results. TP53 gene mutations were found in 7.8% (n=14) of de novo ALL patients. In patients, whose biological material was available TP53 gene mutational status was determined in non-tumor cells (bone marrow and peripheral blood during remission, bone marrow samples after allogeneic hematopoietic stem cells transplantation and in tissue of non-hematopoietic origin) for discriminating germline mutations. The analysis included 5 patients (out of 14 with TP53 mutations), whose non-tumor biological material was available for research. Germline status was confirmed in 4 out of 5 - B-cell ALL (n=3), T-cell ALL (n=1) - investigated patients. Conclusion. Practical value of the research is the observation that the greater part of TP53 gene mutations in patients with Ph-negative B-cell ALL are germinal and associated with LFS.
引用
收藏
页码:763 / 769
页数:7
相关论文
共 50 条
  • [11] Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome
    Tak, Casey R.
    Biltaji, Eman
    Kohlmann, Wendy
    Maese, Luke
    Hainaut, Pierre
    Villani, Anita
    Malkin, David
    Sherwin, Catherine M. T.
    Brixner, Diana I.
    Schiffman, Joshua D.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (05)
  • [12] The Li-Fraumeni syndrome
    Chompret, A
    BIOCHIMIE, 2002, 84 (01) : 75 - 82
  • [13] Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients
    Tian, Panwen
    Zhang, Xiaoyan
    Yang, Sheng
    Fang, Yu
    Yuan, Hongling
    Li, Wei
    Zhu, Honglin
    Zhao, Fangping
    Ding, Jinlei
    Zhu, Yunshu
    Wang, Sizhen
    Sun, Guochen
    Ni, Hongbin
    Ma, Tonghui
    Lei, Ting
    JOURNAL OF GENETICS AND GENOMICS, 2022, 49 (07) : 645 - 653
  • [14] Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician
    Giacomazzi, Cristina Rossi
    Giacomazzi, Juliana
    Netto, Cristina B. O.
    Santos-Silva, Patricia
    Selistre, Simone Geiger
    Maia, Ana Luiza
    de Oliveira, Viviane Ziebell
    Camey, Suzi Alves
    Goldim, Jose Roberto
    Ashton-Prolla, Patricia
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2015, 61 (03): : 282 - 289
  • [15] The Li-Fraumeni syndrome
    Frebourg, T
    BULLETIN DU CANCER, 1997, 84 (07) : 735 - 740
  • [16] Li-Fraumeni syndrome
    Sejben Anita
    Tiszlavicz Laszlo
    Polyak Kornelia
    Kovacs Laszlo
    Maraz Aniko
    Torok Dora
    Lepran Adam
    Ottlakan Aurel
    Furak Jozsef
    ORVOSI HETILAP, 2019, 160 (06) : 228 - 234
  • [17] Spitzoid Melanoma in a Child with Li-Fraumeni Syndrome
    Kollipara, Ramya
    Cooley, Linda D.
    Horii, Kimberly A.
    Hetherington, Maxine L.
    Leboit, Philip E.
    Singh, Vivekanand
    Zwick, David L.
    PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 2014, 17 (01) : 64 - 69
  • [18] Li-Fraumeni Syndrome
    Correa, Hernan
    JOURNAL OF PEDIATRIC GENETICS, 2016, 5 (02) : 84 - 88
  • [19] Early Detection of Adrenocortical Carcinoma in a Child With Li-Fraumeni Syndrome
    Lin, Ming-Tsan
    Shie, Jeng-Jer
    Chang, Julia Hui-Mei
    Chang, Shih-Wen
    Chen, Tse-Ching
    Hsu, Wen-Hu
    PEDIATRIC BLOOD & CANCER, 2009, 52 (04) : 541 - 544
  • [20] An update on the central nervous system manifestations of Li-Fraumeni syndrome
    Orr, Brent A.
    Clay, Michael R.
    Pinto, Emilia M.
    Kesserwan, Chimene
    ACTA NEUROPATHOLOGICA, 2020, 139 (04) : 669 - 687